Drugs / ICP-189
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05370755 | May 2022 → May 2024 | — | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-09-13 | Beijing InnoCare Pharma Tech Co., Ltd. | Regulatory 诺诚健华宣布SHP2抑制剂ICP-189联用 EGFR抑制剂伏美替尼获批临床 innocarepharma.com ↗
中国北京，2023年9月14日 – 生物医药高科技公司诺诚健华（港交所代码：09969；上交所代码：688428）今日宣布，新型蛋白酪氨酸磷酸酶SHP2变构抑制剂ICP-189联用针对表皮生长因子受体（EGFR）突变的口服 EGFR 激酶抑制剂伏美替尼在中国获批开展临床试验。 |
| 2023-04-17 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华多项肿瘤管线数据在2023年美国癌症研究协会（AACR）年会上公布 innocarepharma.com ↗
ICP-189在一组携带活化RTK、RAS、NF1功能丧失或III类BRAF突变的肿瘤细胞系中证明了强大的体外疗效。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-13 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华宣布SHP2抑制剂ICP-189联用 EGFR抑制剂伏美替尼获批临床 innocarepharma.com ↗ |
| 2023-04-17 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华多项肿瘤管线数据在2023年美国癌症研究协会（AACR）年会上公布 innocarepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05370755 ↗ |
| Route | Oral | “Administered orally” NCT05370755 ↗ |